The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.30
Bid: 8.20
Ask: 8.40
Change: 0.12 (1.45%)
Spread: 0.20 (2.439%)
Open: 8.30
High: 8.42
Low: 8.30
Prev. Close: 8.30
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investee company Update: Blue Nalu, Inc

27 Aug 2019 13:21

RNS Number : 2934K
Agronomics Limited
27 August 2019
 

27 August 2019

 

Agronomics Limited

 

 Investee company Update: Blue Nalu, Inc. announces first-of-its-kind commercialization strategy and facility designs for large-scale production of cell-based seafood

 

Agronomics Ltd ("Agronomics" or "ANIC"), the AIM quoted company focusing on making investments in innovative food technologies such as cellular agriculture and cellular aquaculture, notes the announcement released on 22 August 2019 by investee company Blue Nalu, Inc. ("BlueNalu") in which ANIC is a 2.01% shareholder.

 

BlueNalu is a cellular aquaculture company based in San Diego focused on developing lab grown fish. The latest announcement reveals their "First-of-its-kind Commercialization Strategy and Facility Designs for Large-Scale Production of Cell-based Seafood". ANIC are proud to be shareholders in BlueNalu and witness the tremendous progress BlueNalu is making in this exciting field.

 

The BlueNalu announcement is set out below without material changes or adjustments. Plans of the food facility designs can be viewed at https://www.bluenalu.com/pr-82219images.

 

BlueNalu Announces First-of-its-Kind Commercialization Strategy and Facility Designs for Large-Scale Production of Cell-Based SeafoodEach facility anticipated to produce up to 18-million pounds of seafood products  August 22, 2019-San Diego, Calif. BlueNalu, a leading innovative food company producing seafood directly from fish cells, announced today its commercialization strategy and food facility design schematics for large-scale production. This is the first time that any company has provided facility design schematics illustrating the vision for large-scale production of foods via cellular agriculture or aquaculture.

 

"We have developed an optimal strategy for scaling up production of cell-based seafood from a variety of finfish, crustaceans and mollusks to meet global demand," stated Lou Cooperhouse, president & CEO of BlueNalu. "BlueNalu will provide products that are healthy for people, humane for sea life, and sustainable for our planet. As a result, we can have a major impact on supplementing our global supply chain for seafood."

 

BlueNalu has created a five-phase commercialization strategy that starts with R&D and small-scale pilot testing, evolves to a phase that enables market research testing, and culminates in food facilities that are 150,000 sq. ft. under roof. It is anticipated that each facility will produce up to 18-million pounds of finished seafood products per year, or about 72 million four-oz seafood fillets or equivalent units per year. BlueNalu is currently entering its first phase of development, producing whole seafood medallions and fillets at pilot-scale. The company plans to introduce products into a test market in two to three years, and break ground on its first large-scale production facility in five years. This production facility will meet Good Manufacturing Practices (GMP) guidelines and comply with regulatory requirements determined by the FDA for food production.

 

"Over the past year, we have engaged with bioprocessing and food engineering specialists, as well as architects that specialize in food facility design and construction, to determine the optimal process flow and the underlying assumptions that will result in maximum production capacity and flexibility, and minimal capital and operational costs. As can be seen from our schematics, each production facility will look like a hybrid between a microbrewery and a conventional food production facility. BlueNalu's food facilities will produce an array of raw and cooked, fresh and frozen seafood products that are prepared in a trusted and familiar way," said Cooperhouse.

 

The BlueNalu facilities will each be designed to serve regional population centers, initially focused on serving countries in North America, Asia, and Europe, where there is the greatest current and projected per capita consumption of seafood. The company intends to replicate its initial facility to dozens of locations across the globe, making continual operational enhancements along the way, and selecting varieties of fish, product applications, and marketing channels to meet the needs of each selected region. BlueNalu's strategy will contribute to a more stable global supply chain for seafood, in a way that supports the health, sustainability and biodiversity of our ocean.

 

BlueNalu believes that now is the time to move forward with its commercialization strategy in light of significant progress made in the proliferation of its cell lines. "We have recently developed stable fish muscle cell lines of multiple species, and accomplished this without using genetic engineering," said Chris Dammann, PhD, CTO of BlueNalu. "This is critical, since large-scale production of seafood products will require a reliable and consistent supply of real fish muscle cells." 

 

BlueNalu plans to produce seafood from species that are overfished, primarily imported, contain higher levels of mercury and other environmental pollutants, and/or are difficult to farm-raise. It also will focus initially on seafood that commands a premium price and has strong consumer familiarity.

 

"We are pleased that consumers world-wide are embracing alternative proteins," said Cooperhouse. "BlueNalu is excited to announce that large-scale production of cell-based seafood is achievable in the near term."

For more information about BlueNalu, visit bluenalu.com.

 

 

About BlueNalu

 

BlueNalu's mission is to be the global leader in cellular aquaculture, providing customers with great tasting, healthy, safe, and trusted seafood products that support the sustainability and diversity of our ocean. BlueNalu is aligned with 10 of the 17 Sustainable Development Goals (SDG) of the United Nations, a blueprint to achieve a better and more sustainable future for our planet. BlueNalu was founded in 2018 and is based in San Diego, California.

About Agronomics Limited

Agronomics Limited is an investment company focused on opportunities within the nascent industry of modern foods, which are environmentally friendly alternatives to the traditional production of meat and plant-based sources of nutrition. It established an investment policy in April 2019, with a board of directors including Richard Reed, Jim Mellon, David Giampaolo, Denham Eke and Anderson Whamond. The Agronomics team are highly experienced in the food technology field as entrepreneurs, investors and advisors with a significant history of success in the space.

Agronomics believes that the recent developments within cellular agriculture and alternative protein space will provide valuable contributions to meet the demands of increased global population growth and meat consumption in the future. The company sees clean meat as a viable solution to relieve the pressure on arable farming and land usage.

For further information, please contact:

 

Agronomics Limited

Beaumont Cornish Limited

Optiva Securities Limited

Peterhouse Capital Limited

Britton Financial PR

The Company

Nomad

Joint Broker

Joint Broker

Investor Relations

Denham Eke

+44 (0) 1624 639396

Roland Cornish/James Biddle

+44 (0) 207 628 3396

Jeremy King

+44 (0) 203 137 1904

Lucy Williams

+44 (0) 207 469 0936

 

Tim Blackstone

+44 (0)7957 140416

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDPGURGRUPBGPM
Date   Source Headline
29th Oct 20197:00 amRNSInvestment in Shiok Meats Pte. Ltd.
22nd Oct 20192:00 pmRNSCompany Newsletter
17th Oct 20197:00 amRNSInvestment in VitroLabs Inc
15th Oct 20197:00 amRNSInvestment in Rebellyous Foods
8th Oct 20197:00 amRNSNet Asset Value(s)
23rd Sep 20191:00 pmRNSAIM Rule 17 Notification
12th Sep 20197:00 amRNSInvestee Company Update
9th Sep 201911:55 amRNSHolding(s) in Company
5th Sep 20197:00 amRNSSeed Investment in Bond Pets LLC
29th Aug 20197:00 amRNSAgronomics Participates in BlueNalu Fund Raise
28th Aug 20199:42 amRNSNew website launched
27th Aug 20191:21 pmRNSInvestee company Update: Blue Nalu, Inc
12th Aug 201912:51 pmRNSHolding(s) in Company
5th Aug 20197:00 amRNSHolding(s) in Company
31st Jul 20197:00 amRNSNet Asset Value(s)
29th Jul 20197:00 amRNSInvestment in Simply Foods, Inc. (New Age Meats)
5th Jul 20194:40 pmRNSSecond Price Monitoring Extn
5th Jul 20194:35 pmRNSPrice Monitoring Extension
3rd Jul 201912:58 pmRNSResult of Meeting
17th Jun 20192:05 pmRNSSecond Price Monitoring Extn
17th Jun 20192:00 pmRNSPrice Monitoring Extension
17th Jun 201911:00 amRNSPrice Monitoring Extension
13th Jun 20197:00 amRNSEquity Fundraise Closes at £4.5 million
10th Jun 20197:00 amRNSProposed Equity Fundraise
31st May 20199:30 amRNSBoard Appointments
16th Apr 20191:01 pmRNSResult of Meeting
10th Apr 20197:00 amRNSNet Asset Value
29th Mar 20197:00 amRNSCircular and Notice of General Meeting
29th Mar 20197:00 amRNSHalf-year Report
7th Feb 20197:00 amRNSNet Asset Value(s)
28th Dec 20182:20 pmRNSFinal Results
24th Oct 20187:00 amRNSNet Asset Value(s)
16th Aug 20187:00 amRNSInvestment in Blue Nalu, Inc.
18th Jul 20187:00 amRNSNet Asset Value(s)
28th Jun 20187:00 amRNSInvestee Company Update: Summit Therapeutics plc
23rd Apr 20187:00 amRNSNet Asset Value(s)
27th Mar 20189:30 amRNSHalf-year Report
9th Feb 201812:31 pmRNSResult of AGM
8th Feb 20187:00 amRNSChange of Adviser
22nd Jan 20187:00 amRNSNet Asset Value(s)
28th Dec 20174:49 pmRNSFinal Results
19th Oct 20177:00 amRNSNet Asset Value(s)
20th Jul 201711:00 amRNSNAV & Investment in AgeX Therapeutics Inc.
25th Apr 20177:00 amRNSRedemption of Interest in Magna Biopharma Fund
12th Apr 20177:00 amRNSNet Asset Value(s)
29th Mar 20177:00 amRNSHalf-year Report
10th Feb 20175:29 pmRNSResult of AGM
12th Jan 20177:00 amRNSNet Asset Value(s)
23rd Dec 201612:00 pmRNSFinal Results and Notice of AGM
22nd Dec 20162:41 pmRNSLoan to the Diabetic Boot Company Ltd

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.